Quintrio
Home

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

Nexalin Technology, Inc. Common Stock

NXL

Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.51 – $1.64
Volume 6,522
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.93M
Price / earnings
—
Price / book
7.33×
Price / sales
6.96×
EV / sales
7.53×
EV / EBITDA
-0.22×

Profitability

Earnings per share
-$7.58
Return on assets
-285.15%
Return on equity
-3,559.47%
Dividend yield
0%

Liquidity and leverage

Debt / equity
3.62×
Current ratio
0.69×
Quick ratio
0.61×
Cash ratio
0.29×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.3M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NXL, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$78.3K$12.16K$14.95K$171.9K$18.15K$70.59K$41.02K$27.18K
Cost of revenue$22.62K$3.26K$1.82K$21.03K$3.95K$22.84K$13.56K$7.5K
Gross profit$55.68K$8.9K$13.13K$150.87K$14.2K$47.75K$27.46K$19.68K
Selling, general and administrative$2.45M$1.69M$1.79M$2.34M$2.13M$1.44M$1.63M$2.16M
Research and development$219.83K$564.48K$346.38K$224.94K$226.52K$225.77K$406.29K$737.24K
Total operating expenses$2.66M$2.26M$2.13M$2.56M$2.36M$1.67M$2.04M$2.9M
Operating income-$2.61M-$2.25M-$2.12M-$2.41M-$2.35M-$1.62M-$2.01M-$2.88M
Interest expense-$52.77K$129$34$8.24K$2.29K$4.69K$1.1K$3.19K
Income before taxes-$2.66M-$2.24M-$2.1M-$2.38M-$2.28M-$1.58M-$1.99M-$2.83M
Income taxes$0$0$0$0$0$0$0$0
Net income-$2.66M-$2.24M-$2.1M-$2.38M-$2.28M-$1.58M-$1.99M-$2.84M
Net income attributable to common shareholders-$2.66M-$2.24M-$2.1M-$2.38M-$2.28M-$1.58M-$1.99M-$2.84M
EBITDA-$2.57M-$2.22M-$2.11M-$2.41M-$2.34M-$1.62M-$2.01M-$2.87M
Basic earnings per share-$3.43-$3.30-$3.30-$3.80-$3.84-$3.00-$4.50-$7.68
Diluted earnings per share-$3.43-$3.30-$3.30-$3.80-$3.84-$3.00-$4.50-$7.68

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

Nexalin Technology announced the issuance of U.S. Patent No. 12,629,519 covering transcranial alternating current dynamic frequency stimulation methods for anxiety, depression, and insomnia, providing intellectual property protection through 2042. The patent strengthens the company's competitive position in non-invasive deep-brain neurostimulation and supports its HALO™ Clarity platform and Nexalin NeuroCare™ virtual clinic strategy.

GlobeNewswire Inc.

Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents

Nexalin announced a peer-reviewed study published in BMC Psychiatry demonstrating that its DIFS 77.5 Hz high-gamma neurostimulation technology produced statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents. The pilot study of six patients showed clinical improvements with measurable changes in brain-network activity, supporting the company's non-invasive neurostimulation platform. The findings add to Nexalin's growing body of evidence across multiple CNS indications including insomnia, depression, TBI, PTSD, Alzheimer's disease, and ADHD.

GlobeNewswire Inc.

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Nexalin Technology, a leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, has been appointed as the Industry Co-Chair of the National Traumatic Brain Injury (TBI) Registry Coalition. This appointment reflects Nexalin's commitment to advancing TBI advocacy and research, particularly in collaboration with policymakers and stakeholders.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Mar 23, 2007$9.375Apr 16, 2007recurring
Jan 3, 2007$9.375Jan 16, 2007recurring
Sep 28, 2006$9.375Oct 16, 2006recurring
Jun 29, 2006$9.375Jul 17, 2006recurring
Mar 30, 2006$9.375Apr 17, 2006recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 31, 20261-for-30reverse split